Breast Neoplasms |

Breast Neoplasms research study

What is the primary objective of this study?

The purpose of this study is to investigate the relationship between the side effects(especially arthralgia and arthritis) which appear in the patients who are prescribed aromatase inhibitor(AI) and the CYP19 genetic polymorphisms.

Who is eligible to participate?

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Breast Neoplasms



Genetic Polymorphism

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:Aromatase Inhibitor(Femara or Arimidex)Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

CYP19CYP19 genetic polymorphism

Study Status

Unknown status

Start Date: March 2009

Completed Date: September 2010


Type: Observational


Primary Outcome:

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator: Eun Sook Lee, MD, PhD

Lead Sponsor: Korea University Anam Hospital

Collaborator: Korea University

More information:

Discuss Arthralgia